Moreover, the OS benefit associated with GO treatment appeared more pronounced in FLT3–ITD positive than in negative patients, in the whole cohort as well as in CN-AML (Figure 4), although the Gail and Simon test did not reach statistical significance (Figure 3). The gene discussed is FLT3; the disease is acute myeloid leukemia.